A study evaluating persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above who received lung or kidney transplant

You likely can't join if

• •Any history of dementia or any medical condition that moderately or severely impairs cognition. •Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study •History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention •Acute or chronic clinically significant cardiovascular or hepatic functional abnormality, as determined by physical examination or laboratory screening tests. •Recurrent or uncontrolled neurological disorders or seizures. •Any condition which, in the judgment of the investigator, would make IM injection unsafe. •Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the clinical study. •Vaccination with RSV-antigen containing vaccine after 1 or 2 doses received in the parent study •Use of any investigational or non-registered product (drug, vaccine, or medical device) other than the study intervention administration during the period beginning 30 days before the study intervention administration (Day -30 to Day 1), or their planned use during the study period •Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the study intervention administration and ending 30 days after the study intervention administration. In the case of COVID-19 and inactivated/subunit/split influenza vaccines, this time window can be decreased to 14 days before and after study intervention administration. •Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention •History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures. •Any study personnel or their immediate dependents, family, or household members. •Planned move during the study period that will prohibit participating in the study until study end. •Pregnant or lactating female participant. •Female participant planning to become pregnant or planning to discontinue contraceptive precautions. •More than one organ transplanted (i.e., kidney-liver or kidney-other organ(s) transplanted). Dual organ is allowed (double kidney or double lung). •History of events that, in the opinion of the investigator, may put the participant at increased risk for chronic allograft dysfunction. •Participant with an episode of allograft rejection within 3 months (90 days) prior to Visit 1. •Histologic evidence of chronic allograft injury. •Active treatment for acute rejection. •Current diagnosis of malignancy (except non-melanoma skin cancer that does not require systemic therapy). •Any autoimmune conditions or pIMDs that in the opinion of the investigator may put the participant at increased risk. •Any confirmed or suspected HIV infection or primary immunodeficiency disease or ongoing CMV infection with a viremia > 200 IU/mL •Use of anti-CD20 or other B-cell monoclonal antibody agents for the prevention of allograft rejection within 9 months prior to Visit 1. •Use of investigational and non-registered immunosuppressants •Evidence or suspicion of noncompliance or nonadherence to immunosuppressive therapy •Any clinically significant hematologic and/or biochemical laboratory abnormality
• •Previous allograft loss secondary to recurrent primary kidney disease •Evidence of significant proteinuria/albuminuria
• •Diagnosis of acute pulmonary infection within the 2 weeks •Chronic lung allograft dysfunction